Prostaglandin analogue use has grown at the expense of beta-blockers and trabeculectomy in Scotland

Article

The increasing use of prostaglandin analogues in Scotland has led to an increase in prescribing rates and a rapid increase in cost, whilst prescribing of beta-blockers has declined and trabeculectomy rates have fallen, according to a study published in the February 2008 issue of Eye.

The increasing use of prostaglandin analogues in Scotland has led to an increase in prescribing rates and a rapid increase in cost, whilst prescribing of beta-blockers has declined and trabeculectomy rates have fallen, according to a study published in the February 2008 issue of Eye.

Dr Shona Macleod of Aberdeen Royal Infirmary and University of Aberdeen, Scotland and team evaluated the changing trends in glaucoma management in Scotland between 1994 and 2004 by conducting a retrospective analysis of national health statistics. The outcome measures were trabeculectomy rates, corrected for population likely to be at risk of glaucoma (PLG), prescribing volume and cost for glaucoma medications.

Between 1994 and 2004, PLG (calculated from estimates of prevalence in individuals aged 40 years and older, based on published epidemiological studies) increased by 16.6%. During the same time period, trabeculectomy rates fell from 46 per 1000 PLG in 1994 to 15.4 per 1000 PLG in 2004, a decrease of 67%. The cost of prescribing increased by 122% compared with an increase in number of items per 1000 PLG by 27.5%.

In 1994, beta-blockers accounted for 65.2% of prescribed drugs; by 2004, this had dropped to 33%. Since their introduction, the prescribing of prostaglandin analogues has increased rapidly and in 2004, they accounted for 39.4% of prescribed drugs.

Thus the rapidly rising cost of prostaglandin analogues has not impacted negatively on their use, which had in fact, by 2004 in Scotland, overtaken the prescribing of the more traditional beta-blockers and trabeculectomies.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.